TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress
NAR Cancer · 2025
DOI: 10.1093/narcan/zcaf009 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, 2025. Verfasst von Jay R Anand und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, DNA Replication. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
Oncogene activation in normal untransformed cells induces DNA replication stress and creates a dependency on DNA damage response (DDR) mechanisms for cell survival. Different oncogenic stimuli signal via distinct mechanisms in every cancer setting. The DDR is also pathologically reprogrammed and deployed in diverse ways in different cancers. Because mutant KRAS is the driver oncogene in 90% of pancreatic ductal adenocarcinomas (PDACs), here we have investigated DDR mechanisms by which KRAS-induced DNA replication stress is tolerated in normal human pancreatic epithelial cells [human pancreatic nestin-expressing (HPNE) cells]. Using a candidate screening approach, we identify TRIP13 as a KRASG12V-induced messenger RNA that is also expressed at high levels in PDAC relative to normal tissues. Using genetic and pharmacological tools, we show that TRIP13 is necessary to sustain ongoing DNA synthesis and viability specifically in KRASG12V-expressing cells. TRIP13 promotes survival of KRASG12V-expressing HPNE cells in a homologous recombination (HR)-dependent manner. KRASG12V-expressing HPNE cells lacking TRIP13 acquire hallmark HR deficiency phenotypes, including sensitivity to inhibitors of translesion synthesis and poly-ADP ribose polymerase. Established PDAC cell lines are also sensitized to intrinsic DNA damage and therapy-induced genotoxicity following TRIP13 depletion. Taken together, our results expose TRIP13 as an attractive new and therapeutically tractable vulnerability of KRAS-mutant PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
- Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
- Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
- Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States.
- Computational Medicine Program, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States.
ORCID-Profile: Jay R Anand, Sayali Joseph
Förderung
- NCI NIH HHS
- NIH HHS
- NIEHS NIH HHS
- National Institutes of Health
- North Carolina Biotechnology Center
- National Cancer Institute
Zitieren
APA
Anand, J. R., Droby, G. N., Joseph, S., Patel, U., Zhang, X., Klomp, J. A., Der, C. J., Purvis, J. E., Wolff, S. C., Bowser, J. L., & Vaziri, C. (2025). TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress. NAR Cancer. https://doi.org/10.1093/narcan/zcaf009
Vancouver
Anand JR, Droby GN, Joseph S, Patel U, Zhang X, Klomp JA, et al. TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress. NAR Cancer. 2025. doi:10.1093/narcan/zcaf009
BibTeX
@article{Anand2025,
author = {Anand, Jay R and Droby, Gaith N and Joseph, Sayali and Patel, Urvi and Zhang, Xingyuan and Klomp, Jeffrey A and Der, Channing J and Purvis, Jeremy E and Wolff, Samuel C and Bowser, Jessica L and Vaziri, Cyrus},
title = {TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress},
journal = {NAR Cancer},
year = {2025},
doi = {10.1093/narcan/zcaf009}
}
EUVIMED